Siren L.L.C. Sells 87,738 Shares of Taysha Gene Therapies, Inc. $TSHA

Siren L.L.C. lessened its stake in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 1.3% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 6,514,737 shares of the company’s stock after selling 87,738 shares during the quarter. Siren L.L.C. owned about 3.18% of Taysha Gene Therapies worth $9,055,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. Ground Swell Capital LLC acquired a new stake in Taysha Gene Therapies in the 4th quarter worth approximately $25,000. Hsbc Holdings PLC raised its position in shares of Taysha Gene Therapies by 65.6% in the fourth quarter. Hsbc Holdings PLC now owns 20,391 shares of the company’s stock valued at $36,000 after purchasing an additional 8,076 shares during the period. Ameriprise Financial Inc. acquired a new stake in shares of Taysha Gene Therapies in the fourth quarter worth $40,000. BNP Paribas Financial Markets bought a new stake in shares of Taysha Gene Therapies during the 4th quarter worth $41,000. Finally, First Manhattan CO. LLC. bought a new stake in shares of Taysha Gene Therapies during the 4th quarter worth $49,000. 77.70% of the stock is owned by institutional investors.

Taysha Gene Therapies Stock Down 4.7%

TSHA stock opened at $2.83 on Friday. Taysha Gene Therapies, Inc. has a twelve month low of $1.05 and a twelve month high of $3.31. The company has a quick ratio of 12.48, a current ratio of 12.48 and a debt-to-equity ratio of 0.17. The company has a market cap of $772.01 million, a PE ratio of -8.32 and a beta of 0.98. The business’s 50-day simple moving average is $2.66 and its 200 day simple moving average is $2.20.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.02). Taysha Gene Therapies had a negative return on equity of 78.44% and a negative net margin of 1,144.97%.The firm had revenue of $1.99 million during the quarter, compared to the consensus estimate of $1.61 million. On average, research analysts anticipate that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on TSHA shares. Bank of America began coverage on shares of Taysha Gene Therapies in a report on Friday, July 11th. They issued a “buy” rating and a $8.00 target price on the stock. Citigroup reiterated an “outperform” rating on shares of Taysha Gene Therapies in a research note on Thursday, May 29th. Chardan Capital increased their target price on Taysha Gene Therapies from $9.00 to $10.00 and gave the company a “buy” rating in a research note on Tuesday, August 12th. Wells Fargo & Company raised their target price on Taysha Gene Therapies from $7.50 to $8.00 and gave the company an “overweight” rating in a report on Wednesday, August 13th. Finally, Canaccord Genuity Group upped their price target on Taysha Gene Therapies from $9.00 to $11.00 and gave the stock a “buy” rating in a report on Tuesday, June 3rd. Eight research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $8.29.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.